Overview
Produce high-titer lentivirus with this HIV-based Lentivector Packaging Kit
Designed to efficiently package most third-generation lentivectors, the pPACKH1 HIV Lentivector Packaging Kit makes it easy to deliver and express lentiviral constructs in a wide-range of mammalian cells.
- Effectively leverage the powerful lentiviral transduction platform with SBI’s optimized HIV-based and FIV-based packaging systems
- Easily generate high-titer lentiviral preparations
- Efficiently deliver most third-generation lentivector expression constructs
- Successfully reach:
- A wide variety of mammalian cells with VSV-G pseudotyped lentiviral particles
- A broad range of cell types including dividing and quiescent cells, primary cells, stem cells, neuronal cells, endothelial cells, and more
The pPACKH1 Packaging Plasmid Mix consists of three plasmids that produce all the structural and replication proteins needed to transcribe and package an RNA copy of the expression lentivector into recombinant, VSV-G-pseudotyped lentiviral particles. Just co-transfect the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells, isolate virus particles, and transduce into target cells. Upon transduction, the lentivector construct becomes stably integrated into the genome of the target cells for long-term expression of genes, miRNAs, shRNAs, etc.
How It Works
The lentivirus packaging, production, and transduction workflow
Supporting Data
SBI’s pPACKH1 and pPACKF1 Lentivector Packaging Systems possess broad cellular tropism
Resources
Citations
- Ji, D, et al. (2018) Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer. Stem Cell Reports.2018 Nov 12;. PM ID:30449704
- Wu, X, et al. (2018) Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer. Cell Death Dis.2018 Oct 30; 9(11):1102. PM ID:30375371
- Zhao, X, et al. (2018) ADAMTS8 targets ERK to suppress cell proliferation, invasion, and metastasis of hepatocellular carcinoma. Onco Targets Ther.2018 Oct 29; 11:7569-7578. PM ID:30464505
- Qian, D, et al. (2018) MicroRNA-9 modified bone marrow-derived mesenchymal stem cells (BMSCs) repair severe acute pancreatitis (SAP) via inducing angiogenesis in rats. Stem Cell Res Ther.2018 Oct 25; 9(1):282. PM ID:30359310
- Sekiba, K, et al. (2018) Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx–DDB1 interaction. Cellular and Molecular Gastroenterology and Hepatology.2018 Oct 1;. Link:Cellular and Molecular Gastroenterology and Hepatology
- Wang, L, et al. (2018) A pharmacological probe identifies cystathionine β-synthase as a new negative regulator for ferroptosis. Cell Death Dis.2018 Sep 26; 9(10):1005. PM ID:30258181
- Lian, WS, et al. (2018) Chaperonin 60 sustains osteoblast autophagy and counteracts glucocorticoid aggravation of osteoporosis by chaperoning RPTOR. Cell Death Dis.2018 Sep 17; 9(10):938. PM ID:30224697
- Berahovich, R, et al. (2018) CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth. Cancers (Basel).2018 Sep 11; 10(9). PM ID:30208593
- Song, Q, et al. (2018) miR-409 inhibits human non-small cell lung cancer progression by directly targeting SPIN1. Molecular Therapy - Nucleic Acids.2018 Sep 1;. Link:Molecular Therapy - Nucleic Acids
- Song, Q, et al. (2018) miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1. Mol Ther Nucleic Acids.2018 Sep 1; 13:154-163. PM ID:30290307
- Xiang, S, et al. (2018) Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling. J. Exp. Clin. Cancer Res..2018 Aug 6; 37(1):184. PM ID:30081934
- Ma, M, et al. (2018) The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma. Exp Ther Med.2018 Aug 1; 16(2):649-656. PM ID:30112030
- Kim, Y, et al. (2018) Evaluation of Mesenchymal Stem Cell Sheets Overexpressing BMP-7 in Canine Critical-Sized Bone Defects. Int J Mol Sci.2018 Jul 17; 19(7). PM ID:30018197
- Elster, N, et al. (2018) Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. Ther Adv Med Oncol.2018 Jul 13; 10:1758835918778297. PM ID:30023006
- Lv, B, et al. (2018) FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition. Cell. Physiol. Biochem..2018 Jul 12; 48(1):158-172. PM ID:30001540
- Kong, F, et al. (2018) ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene.2018 Jul 9;. PM ID:29985481
- Ma, M, et al. (2018) The clinical significance of Mda‑7/IL‑24 and C‑myb expression in tumor tissues of patients with diffuse large B cell lymphoma. Exp Ther Med.2018 May 29;. Link:Exp Ther Med
- Tse, AP, et al. (2018) Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis.2018 May 25; 7(5):44. PM ID:29799025
- Bosco, EE, et al. (2018) Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. Oncotarget.2018 May 1; 9(33):22960-22975. PM ID:29796165
- Huang, YH, et al. (2018) Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol. Carcinog..2018 Apr 19;. PM ID:29672920
System Biosciences,简称SBI，美国加州湾区新成立的生技公司，致力于独特、创新生物技术之开发，以研发利于基因及蛋白质功能鉴定、研究之崭新方法和工具为宗旨。 现阶段研发重心为RNA干扰（RNAi）研究之相关工具。 System Biosciences (SBI) 致力于开发独特、革新的技术，为客户研究蛋白组学和基因组学功能提供研究工具。SBI 是专业的慢病毒产品公司，提供基于慢病毒的所有相关产品、质粒、试剂盒及相关配套试剂和慢病毒延伸产品如IPS细胞多功能性诱导试剂盒和RNAi筛选文库。
SBI focuses on developing unique, innovative technologies that provide researchers with the tools to investigate and understand genomic and proteomic function. Our mission is to provide tools for the genome-wide analysis of the mechanisms that regulate cellular processes and biological responses.
Headquartered in Palo Alto about 30 miles south of San Francisco, SBI is geographically surrounded by highly successful research biotech companies (e.g., Affymetrix, Life Technologies, and Genentech) and some of the premier life science institutes in the world, including Stanford and the University of California, San Francisco.
As a small private biotechnology company, SBI capitalizes on a rich network of consultants and colleagues and continually collaborates to accelerate its development of innovative and novel applications. Currently, SBI has partnerships with over thirty scientists from several institutes.System Biosciences (SBI) consists of a highly motivated team committed to realizing the potential of its mission to develop and bring to market unique and innovative technology to investigate and understand genomic and proteomic function.
Possessing a diverse range of experience and knowledge, SBI's management and staff bring the skills, talent, and interest needed to support the company's continuing rapid growth.
A strong and proven background in creative research and product development with proficiency in genetic analysis, microarray technology, and cell biology
Extensive business development and management experience
A keen understanding of the needs of life scientists
Expertise in developing, marketing, and supporting consistent, high-quality research products
A clear focus on the need to build and maintain lasting customer relationships through support, service, and close customer interaction
View Products
View Products
View Products
